

## **Supplementary Table Legends**

**Table S1** Third-line and fourth-line chemotherapy regimens used in patients with CUP

## **Supplementary Figure Legends**

**Figure S1** Overall survival in patients with CUP


**Figure S2** Overall survival according to histology in (a) patients with extensive disease and (b) patients with localized disease

**Table S1. Third-line and fourth-line chemotherapy regimens used in patients with CUP**

<b>Chemotherapy regimen</b>	<b>n (%)</b>
<b>Third-line chemotherapy regimen (n = 28)</b>	
Clinical trial	5 (17.9)
FP (5-FU, cisplatin)	4 (14.3)
CAV (cyclophosphamide, doxorubicin, vincristine)	1 (3.6)
VIP (etoposide, ifosfamide, and cisplatin)	1 (3.6)
GP (gemcitabine, carboplatin)	1 (3.6)
CAP (cyclophosphamide, adriamycin, cisplatin)	1 (3.6)
CYVADIC (cyclophosphamide, vincristine, doxorubin, dacarbazine)	1 (3.6)
Docetaxel	1 (3.6)
IP (irinotecan, cisplatin)	3 (10.7)
Others*	10 (35.7)
<b>Fourth-line chemotherapy regimen (n = 6)</b>	
Gemcitabine	1 (16.6)
Ipatasertib	1 (16.6)
VIP (etoposide, ifosfamide, cisplatin)	1 (16.6)
CAV (cyclophosphamide, adriamycin, cisplatin)	1 (16.6)
PC (paclitaxel, cisplatin)	1 (16.6)
Pembrolizumab	1 (16.6)

\*includes EMF, MVAC, NP, ifosfamide, FOLFIRI, AP, IT-MTX, bevacizumab/doxorubicin, AIM, and MF (n = 1 each)

**Figure S1. Overall survival in patients with CUP**



**Figure S2. Overall survival according to histology in (a) patients with extensive disease and (b) patients with localized disease**

